A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how ...

From STAT’s Adam Feuerstein: Another example of why biotech is a tough business.

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

People who use popular diabetes drugs called GLP-1 receptor agonists may be at  increased risk for a serious eye disease, a ...

Camurus and Lilly have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...